Regulatory round-up: 24 August 2026

24 August 2026

Medicines regulators in the USA, Europe and the UK have issued a mix of approvals, safety communications, a batch recall, guidance updates and public warnings over the past week. Generic drug policy, gene therapy and product quality defects account for most of the activity, with no CHMP meeting in August thinning the European approval pipeline.

The latest round-up includes an accelerated approval and two generic drug guidance actions from the US Food and Drug Administration (FDA), a direct healthcare professional communication and a high-profile application withdrawal from the European Medicines Agency (EMA), and a precautionary batch recall from the UK's Medicines and Healthcare products Regulatory Agency (MHRA). The table below summarizes official human medicines regulatory updates from the past seven days.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

More on this story...





Companies featured in this story

More ones to watch >






Company Spotlight



More Features in Pharmaceutical